By successfully encapsulating a vaccine into a spider silk microparticle, Swiss and German researchers have discovered a novel technique that will help fight cancer and certain infectious diseases.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumour cells. However, the desired immune response is is not always guaranteed. In order to strengthen the efficacy of vaccines on the immune system – and in particular on T lymphocytes, specialized in the detection of cancer cells – researchers from the universities of Geneva (UNIGE), Freiburg (UNIFR), Munich, and Bayreuth, in collaboration with the German company AMSilk, have developed spider silk microcapsules capable of delivering the vaccine directly to the heart of immune cells. This process, published in the journal Biomaterials, could also be applied to preventive vaccines to protect against infectious diseases, and constitutes an important step towards vaccines that are stable, easy to use, and resistant to the most extreme storage conditions.
Our immune system is largely based on two types of cells: B lymphocytes, which produce the antibodies needed to defend against various infections, and T lymphocytes. In the case of cancer and certain infectious diseases such as tuberculosis, T lymphocytes need to be stimulated. However, their activation mechanism is more complex than that of B lymphocytes: to trigger a response, it is necessary to use a peptide, a small piece of protein which, if injected alone, is rapidly degraded by the body even before reaching its target.
“To develop immunotherapeutic drugs effective against cancer, it is essential to generate a significant response of T lymphocytes,» says Professor Carole Bourquin, a specialist in antitumor immunotherapies at the faculties of medicine and science of the UNIGE, who directed this work. “As the current vaccines have only limited action on T-cells, it is crucial to develop other vaccination procedures to overcome this issue.”
A virtually indestructible capsule
Scientists used synthetic spider silk biopolymers—a lightweight, biocompatible, non-toxic material that is highly resistant to degradation from light and heat. “We recreated this special silk in the lab to insert a peptide with vaccine properties,» explains Thomas Scheibel, a world specialist of spider silk from the University of Bayreuth who participated in the study. “The resulting protein chains are then salted out to form injectable microparticles.”
Silk microparticles form a transport capsule that protects the vaccine peptide from rapid degradation in the body, and delivers the peptide to the center of the lymph node cells, thereby considerably increasing T lymphocyte immune responses. “Our study has proved the validity of our technique”, reveals Carole Bourquin. “We have demonstrated the effectiveness of a new vaccination strategy that is extremely stable, easy to manufacture and easily customizable.”
Towards a new vaccine model
The synthetic silk biopolymer particles demonstrate a high resistance to heat, withstanding over 100°C for several hours without damage. In theory, this process would make it possible to develop vaccines that do not require adjuvants and cold chains. An undeniable advantage, especially in developing countries where one of the great difficulties is the preservation of vaccines. One of the limitations of this process, however, is the size of the microparticles: while the concept is in principle applicable to any peptide, which are all small enough to be incorporated into silk proteins, further research is needed to see if it is also possible to incorporate the larger antigens used in standard vaccines, especially against viral diseases.
When science imitates nature
“More and more, scientists are trying to imitate nature in what it does best”, adds Scheibel. “This approach even has a name: bioinspiration, which is exactly what we have done here.” The properties of spider silk make it a particularly interesting product: biocompatible, solid, thin, biodegradable, resistant to extreme conditions and even antibacterial, one can imagine multiple applications, including wound dressings or sutures.
Learn more: A new kind of vaccine based on spider silk
The Latest on: Vaccine delivery
via Google News
The Latest on: Vaccine delivery
- Elios Therapeutics Announces Appointment of Phillip Johnson as Chief Financial Officeron June 26, 2019 at 4:30 am
a personalized therapeutic cancer vaccine that uses a proprietary particle delivery system to stimulate the body's immune system to recognize cancer cells as foreign pathogens and fight a patient ... […]
- Technologies Enabling Next Generation Vaccine Development, 2019 Study - Opportunities in Influenza Vaccines, Vaccines for Vector Borne Viral Diseases,on June 25, 2019 at 11:02 am
This report covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin (inorganic and polymeric). The ... […]
- Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technologyon June 25, 2019 at 7:35 am
About ENHANZE® Technology Halozyme's proprietary ENHANZE ® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove ... […]
- SpayVac using vaccines to control wildlife populationson June 25, 2019 at 3:55 am
SpayVac wants to change that by introducing vaccines that will last for at least five years without boosters. Founders highlight a patented nanoparticle delivery system called VacciMax, originally ... […]
- Record-breaking delivery of flu vaccineon June 24, 2019 at 11:23 pm
More than 600,000 flu vaccines have been distributed to general practitioners and immunisation providers in response to the high number of flu cases this season. SA Health’s Director of the ... […]
- Biovet plans mega FMD, brocellosis vaccine facilitieson June 20, 2019 at 6:55 am
Founded in 2006, Biovet aims at increasing its vaccine delivery, multiple animal vaccines testing and challenge studies in Malur, the company said in a statement. The objective is to benefit small ... […]
- Vaccines and global health: In search of a sustainable model for vaccine development and deliveryon June 19, 2019 at 12:32 pm
1 GlaxoSmithKline, 53100 Siena, Italy. 2 Imperial College London, London SW7 2AZ, UK. 3 Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA. 4 Harvard T. H. Chan School of Public Health, Harvard ... […]
- Human Papillomavirus awareness and vaccine acceptability among men who have sex with men from mainland Chinaon June 19, 2019 at 2:31 am
Our results showed that the awareness on HPV and the vaccine were quite poor among MSM in mainland China. To promote the application of HPV vaccination in male populations, appropriate information ... […]
- Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japanon June 18, 2019 at 3:30 am
The vaccine candidate, called M-001 ... READ NOW: There's a way Walmart could beat Amazon when it comes to speedy delivery, and new data shows it's going all in ... […]
via Bing News